When eliquis go generic?

When will Eliquis become available as a generic medication?
The first generic versions of Eliquis (apixaban) are anticipated to become available in the United States in 2026 [1][2]. This timeline is based on the expiration of key patents held by Bristol Myers Squibb and Pfizer [3].

What is the current patent situation for Eliquis?
Eliquis is protected by several patents, with a significant one, U.S. Patent No. 9,901,517, set to expire around late 2026 [1][3]. Other related patents also expire in the years following, influencing the timeline for generic entry [3]. DrugPatentWatch.com tracks these patent expirations and potential market entry dates [4].

Are there any legal challenges affecting Eliquis's patent exclusivity?
There have been legal challenges concerning Eliquis's patents. For instance, Bristol Myers Squibb and Pfizer have sued generic manufacturers for patent infringement, with some of these cases reaching settlement agreements that could allow for earlier generic entry than the full patent term [2][5]. The outcome of these legal proceedings can influence when generic competition begins [5].

How does generic availability impact the cost of Eliquis?
Once generic versions of Eliquis become available, the cost of the medication is expected to decrease significantly [1]. This is a common pattern when new generic competitors enter the market, increasing accessibility for patients [1].

What is apixaban, and what is it used for?
Apixaban is the active ingredient in Eliquis, an anticoagulant medication used to prevent blood clots [6]. It is prescribed for conditions such as atrial fibrillation, deep vein thrombosis (DVT), and pulmonary embolism (PE), as well as to reduce the risk of DVT and PE in certain individuals [6][7].

When did Eliquis first receive FDA approval?
Eliquis was approved by the U.S. Food and Drug Administration (FDA) in December 2012 [8].

Will there be any other anticoagulant medications going generic around the same time?
Other anticoagulant medications, particularly direct oral anticoagulants (DOACs), may also see their patent exclusivity expire in the coming years, leading to generic availability and increased competition in the anticoagulant market [9].

Sources:
[1] https://www.drugpatentwatch.com/
[2] https://www.reuters.com/markets/deals/bristol-myers-pfizer-settle- Eliquis-patent-dispute-drug-could-see-generic-2023-01-31/
[3] https://www.fiercepharma.com/patents/ Eliquis-patent-timeline-what-need-know-about-bms-pfizers-blockbuster-drug
[4] https://www.drugpatentwatch.com/blog/ Eliquis-generics-timeline-patent-expiration
[5] https://www.law360.com/articles/1570708/ Eliquis-patent-fight-expands-bms-pfizer-sue-generic-rival
[6] https://www. Eliquis.com/
[7] https://www.ema.europa.eu/en/medicines/human/EPAR/ Eliquis
[8] https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?fuseAction=DrugFirms.DrugDossier&ID=2107
[9] https://www.drugpatentwatch.com/blog/doac-patent-landscape